Stockreport

BridgeBio Pharma Touts Attruby Uptake, Bayer's Europe Rollout and 2026-28 Pipeline Timelines at Leerink Conf [Yahoo! Finance]

BridgeBio Pharma, Inc.  (BBIO) 
Last bridgebio pharma, inc. earnings: 3/2 08:29 am Check Earnings Report
PDF treatment-naïve share north of 25% and net pricing described as very stable with gross-to-net in the 30–40% range. Bayer's European rollout of acoramidis (Beyonttra) b [Read more]